Pre-Encoded IFN-I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors.

Area of Science:

• Immunology
• Cancer Biology
• Cellular Senescence

Background:

• Solid tumors induce dysfunctional CD8+ T cells, limiting immunotherapy effectiveness.
• Mechanisms driving T-cell dysfunction during tumor growth are not fully understood.
• Spontaneous T-cell priming during tumor growth can lead to poor responses upon vaccination.

Purpose of the Study:

• To investigate the mechanisms behind T-cell dysfunction in solid tumors.
• To identify strategies for improving T-cell responses during cancer vaccination.
• To explore the role of type I interferon (IFN-I) signaling in T-cell dysfunction.

Main Methods:

• Analysis of T-cell priming and memory formation in tumor-bearing models.
• Assessment of T-cell proliferative capacity following boosting vaccination.
• Investigation of gene expression and cellular phenotypes, including senescence.
• Evaluation of the impact of IFN-I signaling blockade on T-cell function and tumor control.

Main Results:

• Tumor-primed memory T cells exhibit poor proliferative responses to boosting vaccination.
• Impeding type I interferon (IFN-I) signaling restores T-cell proliferation and enhances tumor control.
• Tumor-primed memory T cells show unique IFN-I responsiveness and enrichment of DNA repair/cell cycle arrest pathways.
• p21 upregulation and cellular senescence are characteristic features of dysfunctional tumor-primed memory T cells.
• Blockade of p21 or IFN-I signaling improves T-cell proliferative capacity.

Conclusions:

• Type I interferon (IFN-I) signaling contributes to the dysfunction of tumor-primed memory T cells.
• IFN-I hyperresponsiveness is a feature of senescent tumor-primed memory T cells, exacerbating dysfunction.
• Blocking IFN-I signaling represents a potential strategy to enhance T-cell-based cancer immunotherapy.